No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Procter & Gamble Health Limited is engaged in the development, manufacturing, and global distribution of pharmaceuticals and chemical products, with operations both within India and across international markets. Its product range includes various over-the-counter medications, as well as essential vitamins, minerals, and dietary supplements. These offerings are sold under well-known brand names such as Cosome, Polybion, Neurobion, Evion, Nasivion, Livogen, and Seven Seas. Established in 1967, the company was previously known as Merck Limited before officially changing its name to Procter & Gamble Health Limited in May 2019. The firm's corporate headquarters are situated in Mumbai, India, and it operates as a subsidiary of Procter & Gamble Overseas India BV.
www.pghealthindia.comNo one on the platform currently holds PGHL.BO.
No tracked institution reports a position in PGHL.BO as of their last filing.
No one on the platform has traded PGHL.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 90.3% | — | — | — | ||
| Rev. Growth % | 15.6% | 6.9% | ||||
| Profit Margin % | 23.2% | 19.4% | 25.4% | |||
| Free Cash Flow Margin % | 22.9% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $15.6B | +15.4% | $225.00 | $210.86–$239.14 | — | 2 |
| 2028 | $17.7B | +13.3% | $256.00 | $245.76–$266.24 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 2 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-02-06 | $46.70 | $46.70 | +0.0% |
| 2025-11-05 | $46.70 | $53.30 | +14.1% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| PGHL.BOProcter & Gamble Health Limited | $5424.40 | +0.36% | $90.2B | — |
| JLHL.BOJupiter Life Line Hospitals Limited | $275.40 | -1.27% | $91.9B | — |
| JLHL.NSJupiter Life Line Hospitals Limited | $275.55 | -1.29% | $90.3B | — |
| MEDPLUS.BOMedPlus Health Services Limited | $655.25 | -0.81% | $78.7B | — |
| MEDPLUS.NSMedPlus Health Services Limited |
| $656.30 |
| -0.58% |
| $78.8B |
| — |
| METROPOLIS.BOMetropolis Healthcare Limited | $572.30 | -2.25% | $119.1B | — |
| METROPOLIS.NSMetropolis Healthcare Limited | $572.50 | -2.22% | $118.7B | — |
Source: Financial Modeling Prep · peers by sector/industry